45 related articles for article (PubMed ID: 9745396)
1. Primary medical therapy for acromegaly.
Freda PU; Wardlaw SL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3031-3. PubMed ID: 9745396
[No Abstract] [Full Text] [Related]
2. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
3. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
Esposito V; Esposito D; Lo Iudice G
Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
[TBL] [Abstract][Full Text] [Related]
4. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
Colao A; Cappabianca P; Caron P; De Menis E; Farrall AJ; Gadelha MR; Hmissi A; Rees A; Reincke M; Safari M; T'Sjoen G; Bouterfa H; Cuneo RC
Clin Endocrinol (Oxf); 2009 May; 70(5):757-68. PubMed ID: 19178516
[TBL] [Abstract][Full Text] [Related]
5. Short term use of octreotide in acromegaly.
John M; Shah NS; Menon PS
J Assoc Physicians India; 2005 May; 53():477-8. PubMed ID: 16124359
[TBL] [Abstract][Full Text] [Related]
6. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
[TBL] [Abstract][Full Text] [Related]
7. Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question.
Beckers A
J Clin Endocrinol Metab; 2008 Aug; 93(8):2975-7. PubMed ID: 18685119
[No Abstract] [Full Text] [Related]
8. [Acromegaly associated with McCune-Albright syndrome].
Tóth M; Töke J; Kiss E; Bernád I; Miheller P; Szücs N; Rácz K
Orv Hetil; 2002 May; 143(19 Suppl):1070-3. PubMed ID: 12063863
[TBL] [Abstract][Full Text] [Related]
9. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment.
Timsit J; Chanson P; Harris AG; Grass P; Guillausseau PJ; Warnet A; Lubetzki J
Horm Metab Res; 1991 Jan; 23(1):48-9. PubMed ID: 2016081
[No Abstract] [Full Text] [Related]
10. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
[TBL] [Abstract][Full Text] [Related]
11. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
Ezzat S; Ren SG; Braunstein GD; Melmed S
J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
[TBL] [Abstract][Full Text] [Related]
12. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
13. Octreotide treatment of acromegaly during pregnancy.
Mikhail N
Mayo Clin Proc; 2002 Mar; 77(3):297-8. PubMed ID: 11888040
[No Abstract] [Full Text] [Related]
14. Medical management of acromegaly--what and when?
Melmed S
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
[TBL] [Abstract][Full Text] [Related]
15. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
Plöckinger U; Liehr RM; Quabbe HJ
J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
[TBL] [Abstract][Full Text] [Related]
16. Rapid progression of amyotrophic lateral sclerosis in an acromegalic patient after surgical resection of a growth hormone-producing pituitary adenoma.
Mondok A; Aranyi Z; Kovacs GG; Czirjak S; Pusztai P; Varga I; Racz K
Neurologist; 2010 Sep; 16(5):315-8. PubMed ID: 20827122
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.
Chieffo C; Cook D; Xiang Q; Frohman LA
J Clin Endocrinol Metab; 2013 Oct; 98(10):4047-54. PubMed ID: 23969184
[TBL] [Abstract][Full Text] [Related]
18. Octreotide long-acting repeatable for acromegaly.
Cozzi R; Attanasio R
Expert Rev Clin Pharmacol; 2012 Mar; 5(2):125-43. PubMed ID: 22390555
[TBL] [Abstract][Full Text] [Related]
19. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
20. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
